DPI announces close of KELIX bio exit
DPI announces close of KELIX bio exit
According to the firm, the transaction is one of the largest PE exits and M&A deals in Africa’s pharmaceutical sector.
** For the best experience, download the free Africa Private Equity News app Android | iOS **
Development Partners International (DPI) has announced the close of its exit from KELIX bio to Abu Dhabi-based Mubadala Investment Company. According to the firm, the transaction is one of the largest private equity exits and M&A deals in Africa’s pharmaceutical sector over the past 20 years.
DPI created KELIX bio alongside management and co-investors British International Investment and EBRD in 2020. Since then, it has grown rapidly and now exports medicines to over 50 countries across Africa, Latin America, Southeast Asia and the Middle East.
The additional backing of global development finance institutions Proparco, DEG, and FMO also enabled KELIX bio’s rapid growth into new markets and ultimately broadened access to vital specialty generic drugs across emerging markets globally.
Sofiane Lahmar, partner at DPI said, "We are incredibly proud of our role in the creation of KELIX bio. The success of this exit marks an opportunity to thank our LPs and co-investors for their ongoing support as we continue to uncover first-class opportunities to generate growth, value and impact in Africa."
Stay ahead in Africa's private equity and venture capital sector with Africa Private Equity News’ monthly Dealmaker’s Log.